ReviewF1000Research2020
Recent advances in understanding and managing pediatric nonalcoholic fatty liver disease.
Review in F1000Research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Effects of Different Doses of Exercise on Inflammation Markers Among Adolescents With Overweight/Obesity: HEPAFIT Study.The Journal of clinical endocrinology and metabolism · 2022Trial
- Clinically distinct metabotypes of pediatric MASLD identified through unsupervised clustering of NASH CRN data.Nature communications · 2026Article
- Comparative performance of multiple novel obesity indices for MAFLD screening in Chinese children: the body roundness index as a practical predictor.Frontiers in medicine · 2026Article
- Global, regional, and national time trends in prevalence of metabolic dysfunction associated steatotic liver disease among women of reproductive age: an age-period-cohort analysis for the global Burden of Disease 2021 study.Annals of medicine · 2025Article
- Metabolic and Hepatic Profiles of Non-Obese and Obese Metabolic Dysfunction-Associated Steatotic Liver Disease in Adolescents: The Role of FibroScan Parameters,Fibroblast Growth Factor-21, and Cytokeratin-18.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2025Article
- Potential alternative and novel biomarkers for paediatric MAFLD: exploratory evidence from a Chinese cohort.BMC gastroenterology · 2025Article
- Establish a noninvasive model to screen metabolic dysfunction-associated steatotic liver disease in children aged 6-14 years in China and its applications in high-obesity-risk countries and regions.The Lancet regional health. Western Pacific · 2024Article
- The effects of weight loss interventions on children and adolescents with non-alcoholic fatty liver disease: A systematic review and meta-analysis.Obesity science & practice · 2024Review
- The Gut-Liver Axis in Pediatric Liver Health and Disease.Microorganisms · 2023Review
- SFI, a sex hormone binding globulin based nomogram for predicting non-alcoholic fatty liver disease in the Chinese population.Frontiers in endocrinology · 2023Article
- Alterations in DNA methylation associate with fatty liver and metabolic abnormalities in a multi-ethnic cohort of pre-teenage children.Epigenetics · 2022Article
- Possible prediction of obesity-related liver disease in children and adolescents using indices of body composition.Pediatric obesity · 2022Article
- The Role of Macronutrients in the Pathogenesis, Prevention and Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD) in the Paediatric Population-A Review.Life (Basel, Switzerland) · 2022Review
- The Synbiotic Combination ofAntioxidants (Basel, Switzerland) · 2021Article
- Insights into Nonalcoholic Fatty-Liver Disease Heterogeneity.Seminars in liver disease · 2021Review
- Diagnostic and Treatment Dilemmas in Pediatric NAFLD.Clinical liver disease · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nonalcoholic fatty liver disease (NAFLD) represents a spectrum of disease that can range from isolated macrovesicular hepatocellular steatosis to nonalcoholic steatohepatitis (NASH) with or without fibrosis to cirrhosis. The prevalence of NAFLD has increased over several decades, mirroring the global obesity pandemic. NAFLD currently represents the most common etiology of chronic liver disease in children and adolescents worldwide. Disease presentation in childhood strongly suggests that these children may have unique susceptibilities and more severe long-term consequences. Emerging data demonstrate that the pathogenesis of early-onset NAFLD is secondary to a complex interplay involving genetic, metabolic, environmental, and microbiological factors. Such influences may begin
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.